statements

Balaxi Pharmaceuticals Ltd.

NSE: BALAXI

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

20.91-0.1 (-0.43%)

23 Oct, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Balaxi Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	-	-	13.60	45.63	231.33	279.39	336.43	241.29	292.56	270.17	280.11
Cost of Operating Revenue	-	-	10.47	33.58	172.45	196.11	204.45	130.82	167.63	153.07	157.03
Gross Profit	-	-	3.12	12.05	58.89	83.28	131.98	110.48	124.93	117.10	123.08
Gross Margin	-	-	23.0	26.4	25.5	29.8	39.2	45.8	42.7	43.3	43.9
Total Operating Expenses	0.14	0.77	11.96	39.57	189.22	229.70	281.65	196.60	257.15	263.74	273.61
Operating Profit	-0.14	-0.77	1.63	6.06	42.11	49.69	54.79	44.70	35.41	6.43	6.50
Operating Margin	-	-	12.0	13.3	18.2	17.8	16.3	18.5	12.1	2.4	2.3
Financing Income/(Expense) - Net	-0.04	-	-	-	2.04	4.80	1.36	-4.96	-9.10	-2.92	-3.63
Profit before Taxes	-0.17	-0.77	2.44	8.87	44.33	54.52	56.92	2.02	28.67	5.29	6.48
Income Taxes	-	-	0.47	2.77	6.19	6.86	10.96	4.40	3.60	3.88	4.05
Profit after Tax	-0.17	-0.77	1.97	6.10	38.14	47.66	45.96	-2.39	25.07	1.42	2.42
PAT Margin	-	-	14.5	13.4	16.5	17.1	13.7	-1.0	8.6	0.5	0.9
EPS - Basic - ex Extraordinary Items	-0.11	-0.51	1.29	1.22	7.63	9.53	9.16	-0.46	4.54	0.26	0.44
EPS - Diluted - ex Extraordinary Items	-0.11	-0.51	1.29	1.22	7.63	9.53	9.08	-0.46	4.54	0.26	0.44
EBIT	-0.14	-0.77	1.63	6.06	42.11	49.69	54.79	44.70	35.41	6.43	6.50
EBITDA	-0.13	-0.77	1.63	6.07	42.41	50.20	56.54	46.80	37.31	8.58	9.04
EBITDA Margin	-	-	12.0	13.3	18.3	18.0	16.8	19.4	12.8	3.2	3.2

Balance Sheet

Abridged

Understanding Balance Sheet

Balaxi Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	2.34	1.65	5.78	34.86	93.77	141.00	193.51	210.17	242.77	251.43
Long-Term Investments	0.00	0.00	-	-	3.42	4.47	-	-	-	-
Property Plant & Equipment - Net	0.00	0.01	0.01	0.19	1.17	6.03	19.02	17.09	36.31	49.01
Total Non-Current Assets	0.03	0.04	0.33	1.11	5.91	35.47	46.16	48.17	67.58	85.60
Total Assets	2.37	1.69	6.11	35.97	99.68	176.47	239.67	258.34	310.34	337.03
Total Current Liabilities	0.05	0.13	2.59	8.22	34.69	63.27	53.13	54.20	54.53	62.16
Long Term Debt	-	-	-	-	-	-	2.56	1.74	23.05	24.21
Total Non-Current Liabilities	-	-	-	0.00	0.01	0.04	3.66	2.78	24.07	25.80
Total Liabilities	0.05	0.13	2.59	8.23	34.70	63.31	56.79	56.98	78.61	87.95
Total Shareholders' Equity	2.32	1.55	3.52	27.75	64.98	113.16	182.88	201.36	231.74	249.08
Total Equity	2.32	1.55	3.52	27.75	64.98	113.16	182.88	201.36	231.74	249.08
Total Liabilities & Equity	2.37	1.69	6.11	35.97	99.68	176.47	239.67	258.34	310.34	337.03

Cash Flow

Abridged

Understanding Cash Flow Statement

Balaxi Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	-0.13	-0.76	243.45	8.07	41.14	49.98	52.51	-7.34	30.11	18.81
Working Capital - Increase/(Decrease)	0.00	0.09	-394.16	-22.13	-41.15	-15.98	-46.79	10.68	-67.89	-27.05
Net CF from Operating Activities	-0.13	-0.68	-150.71	-14.06	-0.01	34.00	5.72	3.34	-37.78	-8.24
Capital Expenditures - Net	-	0.01	0.54	0.18	2.56	27.34	14.98	1.05	21.76	20.78
Net CF from Investing Activities	2.67	-0.01	-0.54	-0.18	-5.97	-28.45	-10.57	-1.05	-21.76	-20.78
Dividends Paid - Cash - Total	-	-	-	-	-	-	0.50	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	18.10	-	-	18.47	25.79	2.70	-
Debt - LT & ST - Issuance/(Retirement) - Total	-0.24	-	-	-	3.66	-0.02	7.89	5.95	33.86	4.06
Net Cash Flow from Financing Activities	-0.24	-	-	18.10	3.66	-0.02	25.87	31.78	36.65	4.18
Free Cash Flow to Equity	-0.37	-0.69	-151.25	-14.24	1.09	6.64	-1.37	8.24	-25.68	-24.96
Free Operating CF net dividend	-0.13	-0.69	-151.25	-14.24	-2.57	6.66	-9.76	1.77	-59.55	-51.09
Free Operating CF	-0.13	-0.69	-151.25	-14.24	-2.57	6.66	-9.26	1.77	-59.55	-51.09

Business Segment Analysis

FY End:

Mar 26

Balaxi Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Speialized wholesale (100.0%)₹ 42.85 Cr

Revenue / Sales

Speialized wholesale (100.0%)₹ 270.17 Cr

Assets

Speialized wholesale (100.0%)₹ 337.03 Cr

Operating Income

Speialized wholesale (100.0%)₹ 6.43 Cr

Regional Segment Analysis

Balaxi Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Balaxi Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Balaxi Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Speialized wholesale	3	27	15	2	22	43

Frequently Asked Questions

What is the revenue of Balaxi Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Balaxi Pharmaceuticals Ltd. is ₹ 280.11 Cr, reflecting a 1-year growth of -5.90% and a 3-year CAGR of -4.30%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Balaxi Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Balaxi Pharmaceuticals Ltd. is ₹ 2.42 Cr, with a 3-year earnings CAGR of -69.41%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Balaxi Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Balaxi Pharmaceuticals Ltd. is approximately ₹ 6.61 Cr (based on an operating margin of 2.36%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Balaxi Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Balaxi Pharmaceuticals Ltd. is 0.44. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Balaxi Pharmaceuticals Ltd.?

The debt-to-equity ratio of Balaxi Pharmaceuticals Ltd. stands at 0.23. The interest coverage ratio is 1.79x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Balaxi Pharmaceuticals Ltd.?

The estimated book value per share of Balaxi Pharmaceuticals Ltd. is 45.12 (derived from a P/B ratio of 0.46 and market price of ₹ 20.91), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Balaxi Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Balaxi Pharmaceuticals Ltd. is ₹ -8.24 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Balaxi Pharmaceuticals Ltd. report consolidated or standalone financials?

Balaxi Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.